NO20035157D0 - Lungeadministrering av kjemisk modifisert insulin - Google Patents
Lungeadministrering av kjemisk modifisert insulinInfo
- Publication number
- NO20035157D0 NO20035157D0 NO20035157A NO20035157A NO20035157D0 NO 20035157 D0 NO20035157 D0 NO 20035157D0 NO 20035157 A NO20035157 A NO 20035157A NO 20035157 A NO20035157 A NO 20035157A NO 20035157 D0 NO20035157 D0 NO 20035157D0
- Authority
- NO
- Norway
- Prior art keywords
- chemically modified
- pulmonary administration
- modified insulin
- insulin
- pulmonary
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
- 230000002685 pulmonary effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29242301P | 2001-05-21 | 2001-05-21 | |
| PCT/US2002/016464 WO2002094200A2 (en) | 2001-05-21 | 2002-05-21 | Pulmonary administration of chemically modified insulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20035157D0 true NO20035157D0 (no) | 2003-11-20 |
Family
ID=23124608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20035157A NO20035157D0 (no) | 2001-05-21 | 2003-11-20 | Lungeadministrering av kjemisk modifisert insulin |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US6838076B2 (is) |
| EP (1) | EP1395294A4 (is) |
| JP (1) | JP2004535401A (is) |
| KR (1) | KR20030097876A (is) |
| CN (2) | CN1314445C (is) |
| AP (1) | AP1763A (is) |
| AR (1) | AR033903A1 (is) |
| AU (1) | AU2002303869B2 (is) |
| BG (1) | BG108494A (is) |
| BR (1) | BR0209896A (is) |
| CA (1) | CA2447236A1 (is) |
| CO (1) | CO5540371A2 (is) |
| CZ (1) | CZ20033182A3 (is) |
| EA (1) | EA007408B1 (is) |
| EC (1) | ECSP034855A (is) |
| GE (1) | GEP20063917B (is) |
| HR (1) | HRP20030949A2 (is) |
| HU (1) | HUP0400442A2 (is) |
| IL (2) | IL158862A0 (is) |
| IS (1) | IS7043A (is) |
| LT (1) | LT5153B (is) |
| LV (1) | LV13197B (is) |
| MA (1) | MA26185A1 (is) |
| MX (1) | MXPA03010649A (is) |
| MY (1) | MY137181A (is) |
| NO (1) | NO20035157D0 (is) |
| NZ (1) | NZ529572A (is) |
| OA (1) | OA13136A (is) |
| PL (1) | PL366911A1 (is) |
| SK (1) | SK15532003A3 (is) |
| TN (1) | TNSN03116A1 (is) |
| TR (1) | TR200400295T2 (is) |
| WO (1) | WO2002094200A2 (is) |
| YU (1) | YU98503A (is) |
| ZA (1) | ZA200309085B (is) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| BR0209896A (pt) * | 2001-05-21 | 2004-08-17 | Nektar Therapeutics | Composição de insulina para administração pulmonar, e, métodos para suprir insulina a um indivìduo mamìfero, para prover uma composição de insulina não-imunogênica e uma composição de insulina de efeito prolongado para administração ao pulmão de um indivìduo |
| EP1270012A1 (en) * | 2001-06-21 | 2003-01-02 | Pfizer Products Inc. | Use of pulmonary administration of insulin for treatment of diabetes |
| CA2470520A1 (en) * | 2001-12-21 | 2003-07-24 | 3M Innovative Properties Company | Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient |
| ES2425392T3 (es) | 2002-03-20 | 2013-10-15 | Mannkind Corporation | Cartucho para un aparato de inhalación |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| ES2348230T3 (es) | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| DK1596887T3 (da) | 2003-02-26 | 2022-06-20 | Nektar Therapeutics | Polymer-Faktor VIII-konjugat |
| EP1613272B1 (en) * | 2003-04-11 | 2013-12-18 | Antriabio, Inc. | Method for preparation of site-specific protein conjugates |
| EP1491554A1 (en) * | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGylated soluble gp130-dimers useful as a medicament |
| US20070020252A1 (en) * | 2003-08-29 | 2007-01-25 | Ladner Robert C | Modified protease inhibitors |
| US20050089515A1 (en) | 2003-08-29 | 2005-04-28 | Dyax Corp. | Poly-pegylated protease inhibitors |
| GB0328629D0 (en) * | 2003-12-10 | 2004-01-14 | Medpharm Ltd | Metered dose inhalation preparations |
| WO2005115477A2 (en) | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| US7872095B2 (en) | 2004-07-19 | 2011-01-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
| ES2385934T3 (es) | 2004-08-20 | 2012-08-03 | Mannkind Corporation | Catálisis de la síntesis de dicetopiperazina. |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| US20060046852A1 (en) * | 2004-08-26 | 2006-03-02 | Rowe Richard E | Wide area gaming system |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US8245758B2 (en) * | 2006-10-30 | 2012-08-21 | GM Global Technology Operations LLC | Coulomb damped disc brake rotor and method of manufacturing |
| US20080206342A1 (en) * | 2005-01-10 | 2008-08-28 | Rosemary Kovelesky | Compositions and Methods For Increasing the Bioavailability of Pulmonarily Administered Insulin |
| EP1843790A2 (en) * | 2005-01-27 | 2007-10-17 | Novo Nordisk A/S | Insulin derivatives conjugated with structurally well defined branched polymers |
| TWI376234B (en) * | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
| EP1846447B1 (en) | 2005-02-02 | 2013-08-21 | Novo Nordisk A/S | Insulin derivatives |
| ES2428510T3 (es) | 2005-02-02 | 2013-11-08 | Novo Nordisk A/S | Derivados de insulina |
| EP1863840A1 (en) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Pegylated single-chain insulin |
| US20060271011A1 (en) * | 2005-05-25 | 2006-11-30 | Mock Bradley D | Methods and apparatus for indicating when a disposable component of a drug delivery system needs to be replaced |
| US7799344B2 (en) | 2005-09-14 | 2010-09-21 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| US20070136092A1 (en) * | 2005-11-30 | 2007-06-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
| US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
| US20070289258A1 (en) * | 2006-06-14 | 2007-12-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Individualized pharmaceutical selection and packaging |
| US20080033763A1 (en) * | 2005-11-30 | 2008-02-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems related to receiving nutraceutical associated information |
| US20070124218A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized nutraceutical selection and packaging |
| US20110145009A1 (en) * | 2005-11-30 | 2011-06-16 | Jung Edward K Y | Methods and systems related to transmission of nutraceutical associatd information |
| US20080103746A1 (en) * | 2005-11-30 | 2008-05-01 | Searete Llc, A Limited Liability Corporation | Systems and methods for pathogen detection and response |
| US20070124176A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US10296720B2 (en) * | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US7827042B2 (en) * | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
| US20080114577A1 (en) * | 2005-11-30 | 2008-05-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems associated with nutraceutical related assays |
| US8340944B2 (en) * | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US7927787B2 (en) * | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
| US20080052114A1 (en) * | 2005-11-30 | 2008-02-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods related to nutraceuticals |
| US20080004905A1 (en) * | 2006-06-28 | 2008-01-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for analysis of nutraceutical associated components |
| US20070174128A1 (en) * | 2005-11-30 | 2007-07-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
| BRPI0620819A2 (pt) * | 2005-12-30 | 2011-11-22 | Zensun Shangai Science & Technology Ltd | uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero |
| US8039431B2 (en) | 2006-02-22 | 2011-10-18 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| US20070292404A1 (en) * | 2006-03-27 | 2007-12-20 | Biosynexus Incorporated | Antimicrobial polymer conjugates |
| WO2007149594A2 (en) | 2006-06-23 | 2007-12-27 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| PL1873166T3 (pl) | 2006-06-30 | 2011-03-31 | Conaris Res Institute Ag | Ulepszone dimery sgp 130Fc |
| US8298801B2 (en) * | 2006-07-17 | 2012-10-30 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| WO2008015099A2 (en) * | 2006-07-31 | 2008-02-07 | Novo Nordisk A/S | Pegylated, extended insulins |
| AU2007281998B2 (en) * | 2006-08-04 | 2014-02-20 | Pharmathene Inc. | Long half-life recombinant butyrylcholinesterase |
| JP5864834B2 (ja) | 2006-09-22 | 2016-02-17 | ノボ・ノルデイスク・エー／エス | プロテアーゼ耐性のインスリンアナログ |
| US8110655B2 (en) | 2006-11-13 | 2012-02-07 | Auxagen, Inc. | Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor |
| WO2008084051A1 (en) * | 2007-01-12 | 2008-07-17 | Novo Nordisk A/S | Mixtures of pegylated insulin and fast acting insulin for pulmonary administration |
| EP2134181A4 (en) * | 2007-02-28 | 2011-09-28 | Serina Therapeutics Inc | ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME |
| US20140011964A1 (en) | 2007-02-28 | 2014-01-09 | Serina Therapeutics, Inc. | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same |
| ES2563038T3 (es) | 2007-04-30 | 2016-03-10 | Novo Nordisk A/S | Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca |
| WO2009020434A1 (en) * | 2007-08-07 | 2009-02-12 | Nanomaterials Technology Pte Ltd | A process for making micro-sized protein particles |
| US8946201B2 (en) * | 2007-08-27 | 2015-02-03 | Saint Louis University | Methods for inhibiting TGF-β |
| CA2702043A1 (en) * | 2007-10-08 | 2009-04-16 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapies |
| CN101939023B (zh) | 2007-10-16 | 2016-08-03 | 百康有限公司 | 可经口给药的固体药物组合物及其方法 |
| CN101795680A (zh) * | 2007-11-16 | 2010-08-04 | 波苏蛋白试剂公司 | 稳定蛋白质的辅剂 |
| CN101970477B (zh) | 2008-03-14 | 2014-12-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定的胰岛素类似物 |
| JP5749155B2 (ja) | 2008-03-18 | 2015-07-15 | ノボ・ノルデイスク・エー／エス | プロテアーゼ安定化アシル化インスリンアナログ |
| DK2293833T3 (en) | 2008-06-13 | 2016-05-23 | Mannkind Corp | DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| US8488661B2 (en) * | 2008-06-13 | 2013-07-16 | Verizon Patent And Licensing Inc. | Systems and methods for data streaming |
| JP5479465B2 (ja) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | 吸入努力をリアルタイムにプロファイルする対話式機器および方法 |
| TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
| CN102159219B (zh) * | 2008-09-16 | 2015-06-24 | 圣路易斯大学 | 提高转化生长因子-β信号发送的方法 |
| US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
| US8680263B2 (en) | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| WO2010039985A1 (en) | 2008-10-01 | 2010-04-08 | Quintessence Biosciences, Inc. | Therapeutic Ribonucleases |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| CA2748490C (en) | 2008-12-29 | 2016-10-04 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| US8551528B2 (en) | 2009-06-12 | 2013-10-08 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| PE20120918A1 (es) | 2009-07-31 | 2012-08-14 | Sanofi Aventis Deutschland | Profarmacos que comprenden un conjugado de insulina-conector |
| UA108475C2 (uk) * | 2009-07-31 | 2015-05-12 | Санофі-Авентіс Дойчланд Гмбх | Композиція інсуліну тривалої дії |
| EP2488172A4 (en) | 2009-10-13 | 2014-08-13 | Univ Michigan | DENDRIMER COMPOSITION AND METHOD FOR THEIR SYNTHESIS |
| US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
| AU2010340358B2 (en) | 2009-12-21 | 2014-07-24 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
| RS62853B1 (sr) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
| US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
| AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| IL223742A (en) | 2010-06-21 | 2016-06-30 | Mannkind Corp | A dry powder inhaler and preparation for it |
| EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
| CN103635489B (zh) | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| JP2014509603A (ja) | 2011-03-15 | 2014-04-21 | ノヴォ ノルディスク アー／エス | システイン置換を含むヒトインスリン類似体およびヒトインスリン誘導体 |
| CN102675452B (zh) * | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
| MY180552A (en) | 2011-04-01 | 2020-12-02 | Mannkind Corp | Blister package for pharmaceutical cartridges |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
| CN102504022A (zh) * | 2011-11-30 | 2012-06-20 | 苏州元基生物技术有限公司 | 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法 |
| BR112014025132A2 (pt) | 2012-04-11 | 2017-07-11 | Novo Nordisk As | formulações de insulina |
| US9457096B2 (en) | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
| SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| EP2925345B1 (en) | 2012-12-03 | 2018-09-05 | Merck Sharp & Dohme Corp. | Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues |
| AU2014228415B2 (en) | 2013-03-15 | 2018-08-09 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| MX394255B (es) | 2013-07-18 | 2025-03-24 | Mannkind Corp | Composiciones farmaceuticas en polvo seco estables al calor y metodos |
| EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
| KR102302634B1 (ko) | 2013-09-13 | 2021-09-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제 및 이의 조성물 |
| ES2676065T3 (es) | 2013-10-07 | 2018-07-16 | Novo Nordisk A/S | Nuevo derivado de un análogo de la insulina |
| EP3082797A4 (en) | 2013-12-18 | 2017-12-13 | The California Institute for Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| CA2969301A1 (en) | 2014-12-01 | 2016-06-09 | Ferring B.V. | Administration of a selective il-6-trans-signalling inhibitor |
| WO2016089206A2 (en) | 2014-12-01 | 2016-06-09 | Ferring B.V. | Selective il-6-trans-signalling inhibitor compositions |
| CN108602893A (zh) | 2015-12-11 | 2018-09-28 | 戴埃克斯有限公司 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
| EP3442998A4 (en) | 2016-04-12 | 2020-04-01 | Cell And Molecular Tissue Engineering, LLC | SYSTEMS, METHODS AND PRODUCTS FOR MINIMIZING TISSUE REACTIONS AND TISSUE DAMAGE AT AN INFUSION SITE |
| CN109952116B (zh) * | 2016-11-02 | 2021-02-09 | 陶氏环球技术有限责任公司 | 固体非水性凝胶空气增香剂 |
| HUE060149T2 (hu) | 2016-12-16 | 2023-02-28 | Novo Nordisk As | Inzulint tartalmazó gyógyászati készítmények |
| JP2023510854A (ja) | 2020-01-13 | 2023-03-15 | 武田薬品工業株式会社 | 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用 |
| JP2024522196A (ja) | 2021-06-09 | 2024-06-11 | ザ スクリプス リサーチ インスティテュート | 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4652548A (en) | 1981-08-27 | 1987-03-24 | Eli Lilly And Company | Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin |
| US4654324A (en) | 1981-08-27 | 1987-03-31 | Eli Lilly And Company | Human proinsulin pharmaceutical formulations |
| DOP1982004086A (es) | 1981-08-27 | 1988-03-22 | Lilly Co Eli | Formula farmaceutica que comprende insulina humana y proinsulina humana |
| US4839341A (en) | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| EP0400472B1 (en) | 1989-05-27 | 1996-04-03 | Sumitomo Pharmaceuticals Company, Limited | Process for preparing polyethylene glycol derivatives and modified protein. |
| US5342940A (en) | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
| US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US6565841B1 (en) * | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| EP0761683B1 (en) | 1994-05-20 | 2005-02-02 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, process for producing the same, and intermediate compound tehrefor |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| DE19628143A1 (de) | 1996-07-12 | 1998-01-15 | Basf Ag | Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| PT1025125E (pt) | 1997-10-24 | 2003-11-28 | Novo Nordisk As | Derivativos agregados da insulina humana |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| ES2242412T3 (es) | 1998-07-27 | 2005-11-01 | Emisphere Technologies, Inc. | Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos. |
| WO2000033866A1 (en) * | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Pharmaceutical compositions containing insulin |
| US6627228B1 (en) | 1999-01-08 | 2003-09-30 | Emisphere Technologies, Inc. | Polymeric delivery agents and delivery agents compounds |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
| US6323311B1 (en) * | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
| WO2001068141A2 (en) | 2000-03-17 | 2001-09-20 | Maxygen Aps | Dispersions of polypeptide conjugates |
| CA2445494A1 (en) * | 2001-05-11 | 2002-11-21 | Aradigm Corporation | Optimization of the molecular properties and formulation of proteins delivered by inhalation |
| BR0209896A (pt) * | 2001-05-21 | 2004-08-17 | Nektar Therapeutics | Composição de insulina para administração pulmonar, e, métodos para suprir insulina a um indivìduo mamìfero, para prover uma composição de insulina não-imunogênica e uma composição de insulina de efeito prolongado para administração ao pulmão de um indivìduo |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| DE60226613D1 (de) * | 2001-08-16 | 2008-06-26 | Baxter Int | Darreichungsformen welche mikropartikel und treibgas enthalten |
-
2002
- 2002-05-21 BR BR0209896-2A patent/BR0209896A/pt not_active Application Discontinuation
- 2002-05-21 US US10/154,057 patent/US6838076B2/en not_active Expired - Lifetime
- 2002-05-21 IL IL15886202A patent/IL158862A0/xx unknown
- 2002-05-21 SK SK1553-2003A patent/SK15532003A3/sk not_active Application Discontinuation
- 2002-05-21 JP JP2002590921A patent/JP2004535401A/ja active Pending
- 2002-05-21 WO PCT/US2002/016464 patent/WO2002094200A2/en not_active Ceased
- 2002-05-21 YU YU98503A patent/YU98503A/sh unknown
- 2002-05-21 CZ CZ20033182A patent/CZ20033182A3/cs unknown
- 2002-05-21 HR HR20030949A patent/HRP20030949A2/xx not_active Application Discontinuation
- 2002-05-21 HU HU0400442A patent/HUP0400442A2/hu unknown
- 2002-05-21 EP EP02731931A patent/EP1395294A4/en not_active Withdrawn
- 2002-05-21 CA CA002447236A patent/CA2447236A1/en not_active Abandoned
- 2002-05-21 AP APAP/P/2003/002918A patent/AP1763A/en active
- 2002-05-21 GE GE5398A patent/GEP20063917B/en unknown
- 2002-05-21 KR KR10-2003-7014954A patent/KR20030097876A/ko not_active Ceased
- 2002-05-21 AR ARP020101877A patent/AR033903A1/es not_active Application Discontinuation
- 2002-05-21 CN CNB028103556A patent/CN1314445C/zh not_active Expired - Fee Related
- 2002-05-21 TR TR2004/00295T patent/TR200400295T2/xx unknown
- 2002-05-21 AU AU2002303869A patent/AU2002303869B2/en not_active Ceased
- 2002-05-21 OA OA1200300305A patent/OA13136A/en unknown
- 2002-05-21 MY MYPI20021867A patent/MY137181A/en unknown
- 2002-05-21 PL PL02366911A patent/PL366911A1/xx not_active Application Discontinuation
- 2002-05-21 CN CNA2007100855527A patent/CN101045166A/zh active Pending
- 2002-05-21 NZ NZ529572A patent/NZ529572A/en unknown
- 2002-05-21 EA EA200301222A patent/EA007408B1/ru not_active IP Right Cessation
- 2002-05-21 MX MXPA03010649A patent/MXPA03010649A/es active IP Right Grant
-
2003
- 2003-04-01 US US10/405,190 patent/US6890518B2/en not_active Expired - Fee Related
- 2003-07-08 TN TNPCT/US2002/016464A patent/TNSN03116A1/en unknown
- 2003-11-13 IL IL158862A patent/IL158862A/en not_active IP Right Cessation
- 2003-11-19 IS IS7043A patent/IS7043A/is unknown
- 2003-11-20 CO CO03102566A patent/CO5540371A2/es unknown
- 2003-11-20 NO NO20035157A patent/NO20035157D0/no unknown
- 2003-11-20 EC EC2003004855A patent/ECSP034855A/es unknown
- 2003-11-21 LV LVP-03-131A patent/LV13197B/en unknown
- 2003-11-21 MA MA27413A patent/MA26185A1/fr unknown
- 2003-12-17 LT LT2003107A patent/LT5153B/lt not_active IP Right Cessation
- 2003-12-22 BG BG108494A patent/BG108494A/xx unknown
-
2004
- 2004-11-02 US US10/980,652 patent/US20050152848A1/en not_active Abandoned
- 2004-11-21 ZA ZA200309085A patent/ZA200309085B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20035157D0 (no) | Lungeadministrering av kjemisk modifisert insulin | |
| DE60201859D1 (de) | Pharmazeutische Verwendung von N-Carbamoylazol-Derivate | |
| NO20042172L (no) | Insulinmolekyl med forlenget virkningstid | |
| DK3210637T3 (da) | Infusionssæt | |
| DK1383560T4 (da) | Infusionssæt | |
| DE60020518D1 (de) | Verwaltung von Benutzerprofilen | |
| NO20033143D0 (no) | Farmasoytisk preparat | |
| NO20024553L (no) | Absorberende gjenstand av ±ngangsbuksetype | |
| NO20034127D0 (no) | Forbedring av aromainneholdende bestanddeler | |
| EE200300311A (et) | Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim | |
| DK1414409T3 (da) | Stabiliseret oral suspensionsformulering | |
| EE05020B1 (et) | Glburiidi ravimkoostis | |
| NO20044916L (no) | Preparater av sulfinylacetamid | |
| DE60126814D1 (de) | Inhalation von stickoxid | |
| DE60203537D1 (de) | 5ht1-rezeptoragonist enthaltendes arzneimittel | |
| NO20033737L (no) | PEG-konjugater av HGT-NK4 | |
| DE50209245D1 (de) | Neuroprotektives medikament | |
| FI20002114L (fi) | Rekombinanttientsyymien käyttö GDP-L-fukoosin ja fukosyloitujen glykaanien valmistamiseksi | |
| NO20041968L (no) | Anvendelse av cystationin | |
| DE60132511D1 (de) | E-isomeren von fullerenderivate | |
| DE60221342D1 (de) | Niedrig substituierte Hydroxypropylzellulose | |
| EE200300466A (et) | Püridoindolooni derivaatide kasutamine ravimite valmistamiseks | |
| NO20004109L (no) | Stabilisering av formasjoner | |
| ATA8202001A (de) | Medikamentenapplikator | |
| EE200300563A (et) | Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim |